Investigational Drug Information for UGN-102
✉ Email this page to a colleague
What is the drug development status for UGN-102?
UGN-102 is an investigational drug.
There have been 4 clinical trials for UGN-102.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 19th 2021.
The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Carcinoma, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].
There are five hundred and eighty-two US patents protecting this investigational drug and thirty-nine international patents.
Summary for UGN-102
US Patents | 582 |
International Patents | 39,614 |
US Patent Applications | 4,539 |
WIPO Patent Applications | 2,794 |
Japanese Patent Applications | 88 |
Clinical Trial Progress | Phase 2 (2021-02-19) |
Vendors | 72 |
Recent Clinical Trials for UGN-102
Title | Sponsor | Phase |
---|---|---|
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | UroGen Pharma Ltd. | Phase 3 |
A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
Clinical Trial Summary for UGN-102
Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102
US Patents for UGN-102
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
UGN-102 | ⤷ Try a Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Try a Trial |
UGN-102 | ⤷ Try a Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Try a Trial |
UGN-102 | ⤷ Try a Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | ⤷ Try a Trial |
UGN-102 | ⤷ Try a Trial | Compounds as NIK inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for UGN-102
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
UGN-102 | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Try a Trial |
UGN-102 | Canada | CA2961033 | 2034-09-11 | ⤷ Try a Trial |
UGN-102 | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Try a Trial |
UGN-102 | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |